I. Demianets et al. / Polyhedron 182 (2020) 114508
5
4.4. Synthesis 1-Me and 1-F
6.99 (d, J = 7.9 Hz, 2H, C6H4), 6.91 (t, J = 6.7 Hz, 1H, Py), 4.76 (d,
J = 17.2 Hz, 1H, CH2), 4.43 (d, J = 17.2 Hz, 1H, CH2), 2.26 (s, 3H,
Me), 1.81 (s, 15H, 5Me), ꢀ10.39 (s, 1H, IrH). 13C{1H} NMR
(151 MHz, CD2Cl2): d 166.07, 152.71, 141.33, 140.20, 136.51,
128.48, 127.86, 123.46, 119.79, 87.73, 61.60, 21.34, 10.19. IR
*
[Cp IrCl2]2 (100 mg, 0.125 mmol), ligand (H[NNMe] or H[NNF],
0.250 mmol), and triethylamine (38 mg, 0.375 mmol) were stirred
with CH2Cl2 (5 mL) for 3 h at room temperature. Then, all volatiles
were removed in vacuum, the residue was suspended in hexanes
(5 mL) and filtered. The solid was washed with hexane (5 mL)
and then with water (3 ꢁ 5 mL). The yellow solid was dried on
the filter and then crystallized from CH2Cl2/hexanes to give the
product.
1-Me: Orange crystals (156 mg, 93%). Crystals suitable for X-ray
analysis were obtained by slow evaporation of CH2Cl2/hexane solu-
tion. 1H NMR (600 MHz, CD2Cl2): d 8.51 (d, J = 5.2 Hz, 1H, Py), 7.79
(d, J = 8.2 Hz, 2H, C6H4), 7.70 (td, J = 7.7, 1.5 Hz, 1H, Py), 7.26 (t,
J = 6.9 Hz, 1H, Py), 7.21 (d, J = 7.9 Hz, 1H, Py), 7.10 (d, J = 8.0 Hz,
2H, C6H4), 4.76 (br s, 1H, CH2), 4.52 (br s, 1H, CH2), 2.30 (s, 3H,
Me), 1.69 (s, 15H, 5Me). 13C{1H} NMR (101 MHz, CD2Cl2): d
164.66, 151.57, 141.08, 140.91, 138.34, 128.98, 128.40, 124.97,
120.68, 86.82, 58.10, 21.40, 9.65. IR (KBr, cmꢀ1): 1569, 1474,
1447, 1402, 1380, 1355, 1275, 1225, 1134, 1104, 1084, 1056,
1031, 1001, 961, 932, 816, 768, 723, 709, 661, 620, 591, 556,
(KBr, cmꢀ1): 2907 (br), 2100 (
mIrH), 1449, 1289, 1137, 1092, 667,
558. MALDI-MS: m/z calcd for [C23H29IrN2O2S]+ 590.16, found
589.3.
3-F: Pale-yellow crystals (71 mg, 75%). 1H NMR (600 MHz, CD2-
Cl2): d 8.34 (d, J = 5.7 Hz, 1H, Py), 7.73–7.65 (m, 4H, C6H4), 7.53 (td,
J = 7.7, 1.5 Hz, 1H, Py), 7.20 (d, J = 7.8 Hz, 1H, Py), 6.91 (t, J = 6.6 Hz,
1H, Py), 6.84 (t, J = 8.9 Hz, 2H, C6H4), 4.79 (d, J = 17.2 Hz, 1H, CH2),
4.42 (d, J = 17.2 Hz, 1H, CH2), 1.81 (s, 15H, 5Me), ꢀ10.36 (s, 1H, IrH).
13C{1H} NMR (151 MHz, CD2Cl2): d 165.69, 163.67 (d, J = 248.5 Hz),
152.87, 140.43, 136.65, 130.30 (d, J = 8.6 Hz), 123.53, 119.79,
114.61 (d, J = 22.0 Hz), 87.78, 61.54, 10.19. 19F NMR (564 MHz,
CD2Cl2): d ꢀ112.03. IR (KBr, cmꢀ1): 2118 (
mIrH), 1592, 1495, 1284,
1137, 670, 543.
4.7. Synthesis of 4-Me and 4-F
536, 506, 485, 482, 477, 468, 452. MALDI-MS: m/z calcd for [C23
-
Complex 1 (0.160 mmol) and potassium tert-butoxide (90 mg,
0.801 mmol) were stirred with CH2Cl2 (6 mL) for 30 min to give
a dark blue solution of 2. Then, the reaction was continued outside
glovebox under direct sunlight for one hour. After the mixture
turned red it was filtered through a PTFE syringe filter. The result-
ing solution was dried under vacuum and crystallized twice from
CH2Cl2/hexanes to give an off-white crystalline material.
H28IrN2O2S]+ 589.15, found 589.32.
1-F: Yellow crystals (141 mg, 90%). 1H NMR (600 MHz, CD2Cl2):
d 8.51 (d, J = 6.4 Hz, 1H, Py), 7.97 (dd, J = 9.0, 5.4 Hz, 2H, C6H4), 7.71
(td, J = 7.7, 1.5 Hz, 1H, Py), 7.27 (t, J = 7.3 Hz, 1H, Py), 7.22 (d,
J = 8.5 Hz, 1H, Py), 6.96 (t, J = 8.9 Hz, 2H, C6H4), 4.78 (d,
J = 16.9 Hz, 1H, CH2), 4.47 (d, J = 18.0 Hz, 1H, CH2), 1.69 (s, 15H,
5Me). 13C{1H} NMR (151 MHz, CD2Cl2):
d
164.17 (d,
4-Me: Pale-yellow powder (75 mg, 80%). Crystals suitable for X-
ray analysis were obtained by slow evaporation of CH2Cl2/pentane
solution. 1H NMR (600 MHz, CD2Cl2): d 8.27–8.23 (m, 1H), 8.11 (s,
1H), 7.47–7.40 (m, 2H), 7.38 (dt, J = 8.9, 1.4 Hz, 1H), 7.20 (d,
J = 8.0 Hz, 2H), 6.41 (dd, J = 9.0, 6.2 Hz, 1H, CH2), 5.80 (dd,
J = 7.4, 6.2 Hz, 1H, CH2), 2.38 (s, 3H, Me), 1.78 (s, 15H, 5Me). 13C
{1H} NMR (101 MHz, CD2Cl2): d 166.92, 149.87, 146.58, 145.59,
139.72, 136.87, 136.00, 124.07, 124.02, 122.02, 119.64, 88.43,
60.57, 21.03, 8.63. IR (KBr, cmꢀ1): 2914, 1341, 1259, 1215, 1148,
1124, 1086, 849, 833, 802, 764, 728, 683, 664, 617, 601, 583,
559, 541, 510, 483, 464, 456. MALDI-MS: m/z calcd for [C23H27IrN2-
O2S]+ 588.14, found 587.3.
J = 249.0 Hz), 164.39, 151.56, 140.08 (d, J = 2.9 Hz), 138.45,
131.02 (d, J = 8.7 Hz), 125.08, 120.74, 115.15 (d, J = 22.0 Hz),
86.93, 57.98, 9.65. 19F NMR (564 MHz, CD2Cl2): d ꢀ111.48. IR
(KBr, cmꢀ1): 1591, 1497, 1277, 1136, 940, 667, 558. MALDI-MS:
m/z calcd for [C22H25FIrN2O2S]+ 593.13, found 593.35.
4.5. Synthesis of 2-Me and 2-F
Complex 1 (0.080 mmol) and potassium tert-butoxide (45 mg,
0.400 mmol) were stirred with CD2Cl2 (1.0 mL) for 20 min to give
a dark blue solution of 2. It was filtered through a PTFE syringe fil-
ter and then analyzed by 1H NMR. Complex 2 is moisture-, air-, and
light-sensitive, therefore any isolation attempt led to
decomposition.
4-F: Pale-yellow crystals (68 mg, 72%). 1H NMR (600 MHz, CD2-
Cl2): d 8.29 (d, J = 5.2 Hz, 1H, ArH), 7.58 (td, J = 7.7, 1.4 Hz, 1H, ArH),
7.26–7.12 (m, 3H, ArH), 7.03 (t, J = 6.6 Hz, 1H, ArH), 6.57 (td, J = 8.8,
2.5 Hz, 1H, ArH), 5.11 (d, J = 18.3 Hz, 1H, CH2), 4.41 (d, J = 18.3 Hz,
1H, CH2), 1.73 (s, 15H, 5Me). 13C{1H} NMR (151 MHz, CD2Cl2): d
167.25, 163.67 (d, J = 250.3 Hz), 150.38, 149.37, 145.85, 137.67,
124.75, 124.53 (d, J = 8.7 Hz), 121.50 (d, J = 17.1 Hz), 120.27,
110.40 (d, J = 23.1 Hz), 89.19, 61.01, 9.06. 19F NMR (564 MHz, CD2-
Cl2): d ꢀ113.54. IR (KBr, cmꢀ1): 2921, 1557, 1267, 1144, 862, 549.
2-Me: 1H NMR (600 MHz, CD2Cl2): d 8.25 (d, J = 6.8 Hz, 1H, Py),
8.11 (s, 1H, CH), 7.43 (d, J = 7.7 Hz, 2H, C6H4), 7.37 (d, J = 8.9 Hz, 1H,
Py), 7.20 (d, J = 7.8 Hz, 2H, C6H4), 6.40 (d, J = 6.7 Hz, 1H, Py), 5.80 (t,
J = 6.6 Hz, 1H, Py), 2.38 (s, 3H, Me), 1.78 (s, 15H, 5Me).
2-F: 1H NMR (600 MHz, CD2Cl2): d 8.25 (d, J = 7.1 Hz, 1H, Py),
8.12 (s, 1H, CH), 7.59–7.52 (m, 2H, C6H4), 7.39 (d, J = 9.0 Hz, 1H,
Py), 7.12–7.05 (m, 2H, C6H4), 6.42 (ddd, J = 9.0, 6.2, 1.1 Hz, 1H,
Py), 5.81 (t, J = 7.4 Hz, 1H, Py), 1.78 (s, 15H, 5Me). 19F NMR
(564 MHz, CD2Cl2): d ꢀ107.79.
CRediT authorship contribution statement
4.6. Synthesis of 3-Me and 3-F
Ivan Demianets: Conceptualization, Methodology, Formal anal-
ysis, Investigation. Valeriy Cherepakhin: Formal analysis, Investi-
gation. Alexander Maertens: Investigation. Paul J. Lauridsen:
Investigation. Shaama Mallikarjun Sharada: Formal analysis,
Supervision. Travis J. Williams: Conceptualization, Formal analy-
sis, Supervision, Funding acquisition.
Complex 1 (0.160 mmol) and potassium tert-butoxide (90 mg,
0.801 mmol) were stirred with CH2Cl2 (5 mL) for 20 min to give
a dark blue solution of 2. Then, 2 drops of formic acid were added
to cause a sharp color change to orange. The mixture was stirred
for another 10 min with NaHCO3 (50 mg) and then filtered through
a PTFE syringe filter. The resulting solution was dried under vac-
uum and crystallized twice from CH2Cl2/hexanes to afford the
product.
Declaration of Competing Interest
3-Me: Pale-yellow crystals (89 mg, 95%). 1H NMR (600 MHz,
CD2Cl2): d 8.35 (d, J = 5.7 Hz, 1H, Py), 7.55 (d, J = 8.2 Hz, 2H,
C6H4), 7.53 (td, J = 7.7, 1.5 Hz, 1H, Py), 7.20 (d, J = 7.8 Hz, 1H, Py),
The authors declare that they have no known competing finan-
cial interests or personal relationships that could have appeared
to influence the work reported in this paper.